share_log
Moomoo 24/7 ·  Apr 16 07:17
SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment